Cardiac Amyloidosis in HFpEF Tunisian Patients

Last updated: January 14, 2024
Sponsor: University Tunis El Manar
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chest Pain

Heart Failure

Congestive Heart Failure

Treatment

N/A

Clinical Study ID

NCT06201832
13-2023
  • Ages 60-90
  • All Genders

Study Summary

Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations.

Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis.

In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • HFpEF during the previous year
  • IVS thickness of 12mm or greater

Exclusion

Exclusion Criteria:

  • age under 60 years
  • Acute coronary syndrome complicated by HFpEF
  • Congenital heart disease

Study Design

Total Participants: 87
Study Start date:
July 01, 2023
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Security Hospital Forces

    La Marsa, Tunis 2070
    Tunisia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.